Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial

Collins C Iwuji, Joanna Orne-Gliemann, Frank Tanser, Sylvie Boyer, Richard J Lessells, France Lert, John Imrie, Till Bärnighausen, Claire Rekacewicz, Brigitte Bazin, Marie-Louise Newell, François Dabis, ANRS 12249 TasP Study Group, François Dabis, Marie-Louise Newell, Collins Iwuji, Joanna Orne-Gliemann, Nonhlanhla Okesola, John Imrie, Till Bärnighausen, Ruth Bland, Richard Lessells, Frank Tanser, Tulio de Oliveira, Johannes Viljoen, Colin Newell, Kevi Naidu, France Lert, Rosemary Dray-Spira, Joseph Larmarange, Bruno Spire, Sylvie Boyer, Alexandra Calmy, Marie-Laure Chaix, Sophie Karcher, Rodolphe Thiébaut, Kenneth Freedberg, Collins C Iwuji, Joanna Orne-Gliemann, Frank Tanser, Sylvie Boyer, Richard J Lessells, France Lert, John Imrie, Till Bärnighausen, Claire Rekacewicz, Brigitte Bazin, Marie-Louise Newell, François Dabis, ANRS 12249 TasP Study Group, François Dabis, Marie-Louise Newell, Collins Iwuji, Joanna Orne-Gliemann, Nonhlanhla Okesola, John Imrie, Till Bärnighausen, Ruth Bland, Richard Lessells, Frank Tanser, Tulio de Oliveira, Johannes Viljoen, Colin Newell, Kevi Naidu, France Lert, Rosemary Dray-Spira, Joseph Larmarange, Bruno Spire, Sylvie Boyer, Alexandra Calmy, Marie-Laure Chaix, Sophie Karcher, Rodolphe Thiébaut, Kenneth Freedberg

Abstract

Background: Antiretroviral therapy (ART) suppresses HIV viral load in all body compartments and so limits the risk of HIV transmission. It has been suggested that ART not only contributes to preventing transmission at individual but potentially also at population level. This trial aims to evaluate the effect of ART initiated immediately after identification/diagnosis of HIV-infected individuals, regardless of CD4 count, on HIV incidence in the surrounding population. The primary outcome of the overall trial will be HIV incidence over two years. Secondary outcomes will include i) socio-behavioural outcomes (acceptability of repeat HIV counselling and testing, treatment acceptance and linkage to care, sexual partnerships and quality of life); ii) clinical outcomes (mortality and morbidity, retention into care, adherence to ART, virologic failure and acquired HIV drug resistance), iii) cost-effectiveness of the intervention. The first phase will specifically focus on the trial's secondary outcomes.

Methods/design: A cluster-randomised trial in 34 (2 × 17) clusters within a rural area of northern KwaZulu-Natal (South Africa), covering a total population of 34,000 inhabitants aged 16 years and above, of whom an estimated 27,200 would be HIV-uninfected at start of the trial. The first phase of the trial will include ten (2 × 5) clusters. Consecutive rounds of home-based HIV testing will be carried out. HIV-infected participants will be followed in dedicated trial clinics: in intervention clusters, they will be offered immediate ART initiation regardless of CD4 count and clinical stage; in control clusters they will be offered ART according to national treatment eligibility guidelines (CD4 <350 cells/μL, World Health Organisation stage 3 or 4 disease or multidrug-resistant/extensively drug-resistant tuberculosis). Following proof of acceptability and feasibility from the first phase, the trial will be rolled out to further clusters.

Discussion: We aim to provide proof-of-principle evidence regarding the effectiveness of Treatment-as-Prevention in reducing HIV incidence at the population level. Data collected from the participants at home and in the clinics will inform understanding of socio-behavioural, economic and clinical impacts of the intervention as well as feasibility and generalizability.

Trial registration: Clinicaltrials.gov: NCT01509508; South African Trial Register: DOH-27-0512-3974.

Figures

Figure 1
Figure 1
Description of the different components of the ANRS 12249 TasP trial.
Figure 2
Figure 2
ANRS 12249 TasP Trial clusters within Hlabisa sub-district (South Africa).

References

    1. UNAIDS. Report on the Global AIDS Epidemic. Geneva: UNAIDS; 2012. [ ]. Accessed 18 January 2013.
    1. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921–929. doi: 10.1056/NEJM200003303421303.
    1. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394–402. doi: 10.1056/NEJM199908053410602.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, De Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D. et al.Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med. 2011;365:493–505. doi: 10.1056/NEJMoa1105243.
    1. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966–971. doi: 10.1126/science.1228160.
    1. The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: models, data, and questions–towards evidence-based decision-making. PLoS Med. 2012;9:e1001259. doi: 10.1371/journal.pmed.1001259.
    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. doi: 10.1016/S0140-6736(08)61697-9.
    1. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS. 2010;24:729–735. doi: 10.1097/QAD.0b013e32833433fe.
    1. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, Humair S, Klein DJ, Long EF, Phillips AN, Pretorius C, Stover J, Wenger EA, Williams BG, Hallett TB. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245. doi: 10.1371/journal.pmed.1001245.
    1. Hontelez JAC, Lurie MN, Bärnighausen T, Bakker R, Baltussen R, Tanser F, Hallett TB, Newell M-L, De Vlas SJ. Treatment as prevention for HIV in South Africa: different models show consistency in occurrence, but difference in timing of elimination and the overall impact of the intervention. J Int AIDS Soc. 2012;15(Suppl 3)
    1. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM. et al.Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815–1826. doi: 10.1056/NEJMoa0807252.
    1. Sterne JA, May M, Costagliola D, De Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miro JM, Justice AC, Ledergerber B, Fatkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–1363.
    1. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Menan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d’Ivoire. Clin Infect Dis. 2012;54:714–723. doi: 10.1093/cid/cir898.
    1. The ANRS 12249 study group. ANRS 12249 TasP Protocol. ANRS, Paris; (Version 1.2. 08/03/2012). [ ]. Accessed 16 July 2013.
    1. Welz T, Hosegood V, Jaffar S, Batzing-Feigenbaum J, Herbst K, Newell ML. Continued very high prevalence of HIV infection in rural KwaZulu-Natal, South Africa: a population-based longitudinal study. AIDS. 2007;21:1467–1472. doi: 10.1097/QAD.0b013e3280ef6af2.
    1. Tanser F, Barnighausen T, Cooke GS, Newell ML. Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. Int J Epidemiol. 2009;38:1008–1016. doi: 10.1093/ije/dyp148.
    1. Zaidi J, Grapsa E, Tanser F, Newell M, Bärnighausen T. HIV prevalence trends after scale-up of antiretroviral treatment: a population-based study in a poor rural community in KwaZulu-Natal. J Int AIDS Soc. 2012;15(Suppl 3)
    1. Barnighausen T, Tanser F, Newell ML. Lack of a decline in HIV incidence in a rural community with high HIV prevalence in South Africa, 2003–2007. AIDS Res Hum Retroviruses. 2009;25:405–409. doi: 10.1089/aid.2008.0211.
    1. Barnighausen T, Wallrauch C, Welte A, McWalter TA, Mbizana N, Viljoen J, Graham N, Tanser F, Puren A, Newell ML. HIV incidence in rural South Africa: comparison of estimates from longitudinal surveillance and cross-sectional cBED assay testing. PLoS One. 2008;3:e3640. doi: 10.1371/journal.pone.0003640.
    1. Tanser F, Bärnighausen T, Newell M. Identification of Localized Clusters of High HIV Incidence in a Widely Disseminated Rural South African Epidemic: A Case for Targeted Intervention Strategies. Boston, MA (USA): 18th Conference on Retroviruses and Opportunistic Infections (CROI); 2011. Abstract 137.
    1. Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, Thulare H, Newell ML. Cohort Profile: Hlabisa HIV Treatment and Care Programme. Int J Epidemiol. 2011;40:318–326. doi: 10.1093/ije/dyp402.
    1. Maheswaran H, Thulare H, Stanistreet D, Tanser F, Newell ML. Starting a home and mobile HIV testing service in a rural area of South Africa. J Acquir Immune Defic Syndr. 2012;59:e43–e46. doi: 10.1097/QAI.0b013e3182414ed7.
    1. Tanser F, Hosegood V, Barnighausen T, Herbst K, Nyirenda M, Muhwava W, Newell C, Viljoen J, Mutevedzi T, Newell ML. Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol. 2008;37:956–962. doi: 10.1093/ije/dym211.
    1. Tanser F, Hosegood V, Benzler J, Solarsh G. New approaches to spatially analyse primary health care usage patterns in rural South Africa. Trop Med Int Health. 2001;6:826–838. doi: 10.1046/j.1365-3156.2001.00794.x.
    1. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA. Cost-effectiveness of HIV treatment in resource-poor settings–the case of Cote d’Ivoire. N Engl J Med. 2006;355:1141–1153. doi: 10.1056/NEJMsa060247.
    1. Hontelez JA, De Vlas SJ, Tanser F, Bakker R, Barnighausen T, Newell ML, Baltussen R, Lurie MN. The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS One. 2011;6:e21919. doi: 10.1371/journal.pone.0021919.
    1. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, Mayaud P, Changalucha J, Nicoll A, Ka-Gina G, Newell J, Mugeye K, Mabey D, Hayes R. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346:530–536. doi: 10.1016/S0140-6736(95)91380-7.
    1. Tanser F, Barnighausen T, Hund L, Garnett GP, McGrath N, Newell ML. Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet. 2011;378:247–255. doi: 10.1016/S0140-6736(11)60779-4.
    1. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents Recommendations for a public health approach (2010 revision) Geneva: World Health Organisation; [ ]. Accessed18 January 2013.
    1. National Department of Health. Clinical guidelines for the management of HIV/AIDS in adults and adolescents. Republic of South Africa: Department of Health; 2010.
    1. Chaiyachati K, Hirschhorn LR, Tanser F, Newell ML, Barnighausen T. Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa. AIDS Patient Care STDS. 2010;25:163–170.
    1. Boyer S, Clerc I, Bonono CR, Marcellin F, Bile PC, Ventelou B. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors. Soc Sci Med. 2011;72:1383–1392. doi: 10.1016/j.socscimed.2011.02.030.
    1. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, Raffi F, Journot V, Moatti JP. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr. 2001;28:232–239.
    1. Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, Quillet C, Ngeth C, Ferradini L, Delfraissy JF, Laureillard D. Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther. 2008;13:697–703.
    1. Duracinsky M, Herrmann S, Berzins B, Armstrong AR, Kohli R, Le Coeur S, Diouf A, Fournier I, Schechter M, Chassany O. The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV/AIDS. J Acquir Immune Defic Syndr. 2012;59:498–505. doi: 10.1097/QAI.0b013e318245cafe.
    1. Duracinsky M, Lalanne C, Le Coeur S, Herrmann S, Berzins B, Armstrong AR, Lau JT, Fournier I, Chassany O. Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument-specific to HIV disease. J Acquir Immune Defic Syndr. 2012;59:506–515. doi: 10.1097/QAI.0b013e31824be3f2.
    1. Holzemer WL, Uys LR, Chirwa ML, Greeff M, Makoae LN, Kohi TW, Dlamini PS, Stewart AL, Mullan J, Phetlhu RD, Wantland D, Durrheim K. Validation of the HIV/AIDS Stigma Instrument - PLWA (HASI-P) AIDS Care. 2007;19:1002–1012. doi: 10.1080/09540120701245999.
    1. Ukoumunne OC, Carlin JB, Gulliford MC. A simulation study of odds ratio estimation for binary outcomes from cluster randomized trials. Stat Med. 2007;26:3415–3428.
    1. Mancl LA, DeRouen TA. A covariance estimator for GEE with improved small-sample properties. Biometrics. 2001;57:126–134. doi: 10.1111/j.0006-341X.2001.00126.x.
    1. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. Aids. 2009;23(11):1397–1404. doi: 10.1097/QAD.0b013e32832b7dca.
    1. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2011;8:CD009153.
    1. World Health Organisation. Guidance on Couples HIV Testing and Counselling including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples. Geneva: World Health Organisation; 2012. (Recommendations for a public health approach). In.
    1. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organisation; 2013. (Recommendations for a public health approach). In.
    1. Chi BH, Cantrell RA, Zulu I, Mulenga LB, Levy JW, Tambatamba BC, Reid S, Mwango A, Mwinga A, Bulterys M. et al.Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol. 2009;38(3):746–756. doi: 10.1093/ije/dyp004.
    1. Maqutu D, Zewotir T, North D, Naidoo K, Grobler A. Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. Afr J AIDS Res. 2010;9(2):117–124. doi: 10.2989/16085906.2010.517478.
    1. Uy J, Armon C, Buchacz K, Wood K, Brooks JT. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr. 2009;51(4):450–453. doi: 10.1097/QAI.0b013e3181acb630.
    1. Barnighausen T, Bloom DE, Humair S. Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(52):21271–21276. doi: 10.1073/pnas.1209017110.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir